首页 › 期刊 › 医学 › The Lancet Child & Adolescent Health
The Lancet Child & Adolescent Health
出版商:Elsevier · ISSN:2352-4642, 2352-4650 · 国家/地区:GB · 类型:journal · 官网:https://www.journals.elsevier.com/the-lancet-child-and-adole...
研究主题:Child and Adolescent Health · Childhood Cancer Survivors' Quality of Life · Adolescent and Pediatric Healthcare · Neonatal Respiratory Health Research · Child Nutrition and Water Access
核心指标
- 影响因子(JCR 2024):13.400
- JCR 分区:Q1(PEDIATRICS(SCIE))
- 中科院分区(2025):医学 1区(Top);小类:PEDIATRICS 儿科 1区
- 新锐分区(2026):医学 1区
- SJR:4,365(Q1)
- h-index:116
- i10 指数:687
- 近两年篇均被引:4.94
- 载文量 1956 · 总被引 66732
逐年趋势
- 近年影响因子:2020 11.3 → 2021 37.7 → 2022 36.4 → 2023 19.9 → 2024 15.5
- 近年 SJR:2021 4.38(Q1) → 2022 4.18(Q1) → 2023 4.23(Q1) → 2024 4.29(Q1) → 2025 4.37(Q1)
投稿参考
- 版面费(APC)约 $5780 USD(以期刊官网为准)
- 提供 LaTeX 投稿模板(elsarticle.cls)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- Kidney International Supplements — IF 89.6 · JCR Q1 · 中科院2区
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Signal Transduction and Targeted Therapy — IF 81.2 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
常见问题
《The Lancet Child & Adolescent Health》的影响因子是多少?
根据 JCR 2024 年数据,《The Lancet Child & Adolescent Health》的最新影响因子(IF)为 13.400。
《The Lancet Child & Adolescent Health》是几区期刊?
《The Lancet Child & Adolescent Health》中科院分区(2025年版)为医学1区(Top 期刊),JCR 分区为 Q1。
《The Lancet Child & Adolescent Health》的版面费(APC)是多少?
根据 OpenAlex 收录的价目,《The Lancet Child & Adolescent Health》的文章处理费(APC)约为 $5780 美元。实际费用与豁免政策请以期刊官网为准。
本刊近期代表论文
- Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial (2026 · 被引 1)
- Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study (2025 · 被引 33)
- Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up (2025 · 被引 15)
- Quantifying the fatal and non-fatal burden of disease associated with child growth failure, 2000–2023: a systematic analysis from the Global Burden of Disease Study 2023 (2025 · 被引 10)
- International expert consensus statement on PICU admission and early critical care management for paediatric patients following haematopoietic cell transplant and immune effector cell therapy. (2025 · 被引 4)
- Risk stratification of childhood infection using host markers of immune and endothelial activation in Asia (Spot Sepsis): a multi-country, prospective, cohort study (2025 · 被引 3)